FDA has approved Wegovy, Trulicity, Victoza, Mounjaro, Ozempic and Rybelsus/Ozempic tablets for this, in the words of each label below. SELECT (Semaglutide): In people with heart disease and overweight or obesity, without diabetes, heart death, heart attack or stroke happened in 6.5% on semaglutide 2.4 mg against 8.0% on placebo (hazard ratio 0.80). ClinicalTrials.gov lists 97 trials of these medicines on it: 13 with posted results and 16 recruiting now.
Read from the registry and PubMed every day. The newest update here is Nov 4, 2026.
The approved use, word for word from each current label.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide · 17,604 people · Better than the comparison · Placebo-controlled randomized trial
In people with heart disease and overweight or obesity, without diabetes, heart death, heart attack or stroke happened in 6.5% on semaglutide 2.4 mg against 8.0% on placebo (hazard ratio 0.80).
Tirzepatide vs dulaglutide · 13,299 people · Mixed · Head-to-head randomized trial
In type 2 diabetes with heart disease, heart death, heart attack or stroke happened in 12.2% on tirzepatide against 13.1% on dulaglutide. That met the test for no worse (noninferior), not the test for better (P = 0.09).
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 42 | 3 | 11 |
| Liraglutide | 21 | 7 | 0 |
| Exenatide | 18 | 1 | 0 |
| Tirzepatide | 7 | 1 | 1 |
| Orforglipron | 3 | 0 | 2 |
| Dulaglutide | 2 | 1 | 1 |
| Retatrutide | 2 | 0 | 0 |
| MariTide | 1 | 0 | 0 |
| Mazdutide | 1 | 0 | 1 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| SELECTSemaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | Semaglutide | Phase 3 | 17,604 | Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (Participants), From randomisation (week 0) up to 240 weeks. Semaglutide: 569; Placebo: 701. |
| REWINDResearching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) | Dulaglutide | Phase 3 | 9,901 | Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (Participants), From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years). Placebo: 663; Dulaglutide: 594. |
| SURPASS-4A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Tirzepatide | Phase 3 | 2,002 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 52. 10 mg Tirzepatide: -2.43; 15 mg Tirzepatide: -2.58; Insulin Glargine: -1.44. |
| STRIDEA Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Semaglutide | Phase 3 | 792 | Change in Maximum Walking Distance on a Constant Load Treadmill Test (Ratio of maximum walking distance), Baseline (week 0), end of treatment (week 52). Semaglutide: 1.21; Placebo: 1.08. |
| NCT03038620Impact of Liraglutide 3.0 on Body Fat Distribution | Liraglutide | Phase 4 | 235 | Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI (percentage of reduction in VAT), Baseline, 40 weeks. Liraglutide 3.0 mg: 12.49; Placebo: 1.63. |
| LIPTLIPT - Liraglutide in Polycystic Ovary Syndrome | Liraglutide | Phase 4 | 72 | Change in Endogenous Thrombin Potential (ETP) (nMolar x minutes), at time 0 and 26 weeks. Liraglutide: -56.7; Placebo: -8.2. |
| NCT03151005The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | Liraglutide | Phase 4 | 70 | Assessment of Reproductive Functions (mIU/ml), 12 weeks. Metformin-GLP-1 Receptor Agonist: 5.52; Metformin-Oral Contraceptive(OC): 5.33. |
| STARDUSTLiraglutide and Peripheral Artery Disease | Liraglutide | Phase 4 | 60 | Peripheral Transcutaneous Oxygen Pressure (mmHg), 6 months. Liraglutide Group: 54.2; Control Group: 43.4. |
| NCT00736229Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients | Exenatide | Phase 4 | 40 | Median Glucose Values From Steady State Through 48 Hours or Until Discharge. (mg/dL), 1-48 hours. Exenatide: 132; Moderate: 127; Intensive: 105. |
| NCT03260881Liraglutide Effects on Epicardial Fat Inflammatory Genes | Liraglutide | Phase 4 | 38 | On ClinicalTrials.gov |
| NCT04216589Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) | Semaglutide | Phase 2 | 51 | On ClinicalTrials.gov |
| ON TARGET DMComparison of Type 2 Diabetes Pharmacotherapy Regimens | Liraglutide | Not phased | 241,981 | Incidence of 3-point Major Adverse Cardiovascular Events (MACE) (Participants), 2.5 years. SU Initiators: 11,348; DPP4 Initiators: 393; SGLT2i Initiators: 424; GLP-1RA Initiators: 296. |
| NCT03010683Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus | Liraglutide | Not phased | 60 | Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R. (m/s), Baseline, 3 months, 6 months and 12 months, Baseline. Liraglutide: 11.8; Metformin: 11.2. |
The registry page names each site and who can enroll. Ask your clinician before joining one.
The 15 largest of 16 recruiting.
Meta-analysis · Crit Pathw Cardiol · Nov 2, 2026 · Marino G et al.
Meta-analysis · Diabetes Obes Metab · Oct 27, 2026 · Fujii A et al.
Meta-analysis · Monaldi Arch Chest Dis · Oct 26, 2026 · Saleem MF et al.
Randomized trial · Lancet · Sep 30, 2026 · Klein KR et al.
Meta-analysis · Diabetes Ther · Sep 1, 2026 · Ghafoury R et al.
Randomized trial · Diabetes Obes Metab · Aug 17, 2026 · Ruotolo G et al. · cited by 1
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
Written from each source's own record as it changes. Every change on GLPcompare
SELECT (Semaglutide, 17,604 people): In people with heart disease and overweight or obesity, without diabetes, heart death, heart attack or stroke happened in 6.5% on semaglutide 2.4 mg against 8.0% on placebo (hazard ratio 0.80).
Yes: Wegovy, Trulicity, Victoza, Mounjaro, Ozempic and Rybelsus/Ozempic tablets. Wegovy's label: to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight.
Plans decide, and they usually tie coverage to a medicine's approved uses, so Wegovy, Trulicity, Victoza, Mounjaro, Ozempic and Rybelsus/Ozempic tablets are the place to start. Ask your plan whether it covers the medicine for this diagnosis and whether it needs prior authorization.
Semaglutide, with 42 registered trials on it, then Liraglutide with 21. More trials do not mean better results: read what each posted.
16 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.